Breast Cancer | Specialty

MA.31 Trial: Taxane With Lapatinib or Trastuzumab

June 9th 2013

CLEOPATRA Trial: Frontline Pertuzumab for HER2+ MBC

June 9th 2013

Frontline T-DM1 in HER2+ Metastatic Breast Cancer

June 9th 2013

EMILIA Trial: T-DM1 in Metastatic Breast Cancer

June 9th 2013

Management of mTOR Inhibitor Side Effects in Breast Cancer

June 9th 2013

BOLERO-2 Trial: Everolimus in Metastatic Breast Cancer

June 9th 2013

Combination of Anastrozole and Fulvestrant in MBC

June 9th 2013

Introduction and Exploration of Fulvestrant in Breast Cancer

June 9th 2013

Dr. Rutgers Compares ART or ALND in Breast Cancer

June 7th 2013

Emiel J. Rutgers, MD, surgical oncologist, Netherlands Cancer Institute, Amsterdam, discusses a study analyzing radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients.

Dr. Finn on the Future of Palbociclib in Breast Cancer

June 6th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the potential impact of the cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in the treatment of patients with ER-positive metastatic breast cancer.

Axillary Radiotherapy Equal to Surgery in Early Breast Cancer

June 6th 2013

Women with early sentinel lymph node-positive breast cancer achieve as much of a disease-free and survival benefit from axillary radiotherapy as they do from axillary lymph node dissection with significantly less risk of lymphedema.

Dr. Churpek on Gene Mutations in Breast Cancer

June 6th 2013

Jane E. Churpek, MD, discusses a study that found the inherited mutations in breast cancer genes in African American breast cancer patients were revealed by targeted genomic capture and next-generation sequencing.

Revisiting HER2: Recent Research Shakes Views on Famed Marker

June 5th 2013

New research suggests that HER2-targeted drugs may actually have much broader applications, benefiting patients who are not designated HER2-positive by routine testing.

Optimal Paclitaxel Schedule Identified for Early-Stage Breast Cancer

June 4th 2013

Low-dose weekly paclitaxel is as effective and has fewer side effects than the standard biweekly schedule for patients with early-stage breast cancer.

Dr. Hudis Highlights Two Abstracts From ASCO 2013

June 4th 2013

Clifford A. Hudis, MD, ASCO President-Elect, describes the focus on global medicine at the 2013 American Society of Clinical Oncology Annual Meeting.

More Evidence for 10-Years of Tamoxifen in ER+ Breast Cancer

June 3rd 2013

A British study has confirmed that 10 years of adjuvant tamoxifen substantially reduces late breast cancer recurrence and mortality among women with estrogen receptor-positive disease.

Richard Gray on a Longer Duration of Tamoxifen

June 2nd 2013

Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.

Dr. O'Shaughnessy on Everolimus in Breast Cancer

June 1st 2013

Joyce A. O'Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center, describes potentially practice changing findings from the BOLERO-3 trial.

Wicha Sees Potential for Significant Expansion of Anti-HER2 Therapy

May 31st 2013

Max S. Wicha, MD, is an internationally renowned research expert in the field of breast oncology. His lab was part of the first team to discover stem cells in breast cancer, and he is among the most highly cited investigators in the field of cancer stem cells.

Dr. Piccart on the Success of Trastuzumab

May 30th 2013

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the success of trastuzumab for the treatment of breast cancer.